JNJ

188.94

+1.67%↑

ABT

124.53

-0.36%↓

TMO

560.5

-0.93%↓

ISRG

531.35

-1.39%↓

DHR

216.24

-0.08%↓

JNJ

188.94

+1.67%↑

ABT

124.53

-0.36%↓

TMO

560.5

-0.93%↓

ISRG

531.35

-1.39%↓

DHR

216.24

-0.08%↓

JNJ

188.94

+1.67%↑

ABT

124.53

-0.36%↓

TMO

560.5

-0.93%↓

ISRG

531.35

-1.39%↓

DHR

216.24

-0.08%↓

JNJ

188.94

+1.67%↑

ABT

124.53

-0.36%↓

TMO

560.5

-0.93%↓

ISRG

531.35

-1.39%↓

DHR

216.24

-0.08%↓

JNJ

188.94

+1.67%↑

ABT

124.53

-0.36%↓

TMO

560.5

-0.93%↓

ISRG

531.35

-1.39%↓

DHR

216.24

-0.08%↓

Search

Emergent BioSolutions Inc

Ouvert

SecteurSoins de santé

12.49 32.45

Résumé

Variation du prix de l'action

24h

Actuel

Min

9.22

Max

13.34

Chiffres clés

By Trading Economics

Revenu

-80M

-12M

Ventes

-81M

141M

P/E

Moyenne du Secteur

3.713

37.003

Marge bénéficiaire

-8.517

Employés

900

EBITDA

-131M

1.6M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+43.62% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

197M

520M

Ouverture précédente

-19.96

Clôture précédente

12.49

Sentiment de l'Actualité

By Acuity

50%

50%

176 / 373 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Emergent BioSolutions Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 oct. 2025, 23:28 UTC

Actions en Tendance

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 oct. 2025, 23:07 UTC

Résultats

Prudential PLC 3Q New Business Profit Up 13%

30 oct. 2025, 00:00 UTC

Résultats

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 oct. 2025, 00:00 UTC

Résultats

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 oct. 2025, 00:00 UTC

Résultats

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 oct. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 oct. 2025, 23:40 UTC

Résultats

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 oct. 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 oct. 2025, 23:25 UTC

Résultats

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 oct. 2025, 22:51 UTC

Résultats

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 oct. 2025, 22:45 UTC

Résultats

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 oct. 2025, 22:41 UTC

Résultats

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 oct. 2025, 22:41 UTC

Résultats

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 oct. 2025, 22:09 UTC

Résultats

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 oct. 2025, 22:08 UTC

Market Talk
Résultats

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 oct. 2025, 21:58 UTC

Résultats

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 oct. 2025, 21:58 UTC

Résultats

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 oct. 2025, 21:57 UTC

Résultats

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 oct. 2025, 21:54 UTC

Résultats

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 oct. 2025, 21:46 UTC

Résultats

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 oct. 2025, 21:43 UTC

Résultats

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 oct. 2025, 21:43 UTC

Résultats

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 oct. 2025, 21:42 UTC

Résultats

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 oct. 2025, 21:42 UTC

Résultats

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 oct. 2025, 21:41 UTC

Résultats

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 oct. 2025, 21:41 UTC

Résultats

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 oct. 2025, 21:41 UTC

Résultats

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 oct. 2025, 21:41 UTC

Résultats

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 oct. 2025, 21:40 UTC

Résultats

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 oct. 2025, 21:39 UTC

Résultats

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Comparaison

Variation de prix

Emergent BioSolutions Inc prévision

Objectif de Prix

By TipRanks

43.62% hausse

Prévisions sur 12 Mois

Moyen 13.5 USD  43.62%

Haut 15 USD

Bas 12 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

4.95 / N/ASupport & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

176 / 373Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat